Pnd73 - The Impact of Modelling Subsequent Treatment on Estimates of Cost-Effectiveness: An Analysis of Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2039
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

Journal of Managed Care Pharmacy
2009English

Pnd60 - Cost-Effectiveness of Teriflunomide for the Treatment of Relapsing-Remitting Multiple Sclerosis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2010English

Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis

Farmeconomia. Health economics and therapeutic pathways
2018English

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics

Archives of Neurology
1999English

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis

Advances in Therapy
MedicinePharmacology
2019English

PND14 Budgetary Impact of the Treatment of Relapsing-Remitting Multiple Sclerosis in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Characteristics of Pediatric Patients With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Agents

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy